Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. It also focuses on artificial intelligence (AI) and digital pathology solutions. The Company’s services primarily are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 19.27% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 11.04B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 38.22%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 38.22%.
Overvalued
The company’s latest PE is 22.79, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 110.61M shares, decreasing 2.78% quarter-over-quarter.
Held by EDGEPOINT CANADIAN PORTFOLIO
Star Investor EDGEPOINT CANADIAN PORTFOLIO holds 2.26M shares of this stock.